HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.

5th Edition of

Chemistry World Conference

June 02-04, 2025 | Rome, Italy

Drug Development

Drug Development

Drug development is a multifaceted journey characterized by meticulous research, rigorous testing, and regulatory scrutiny, aiming to bring novel therapeutics to the market to address unmet medical needs and improve patient outcomes. It begins with the identification of a potential target, often a molecule or biological pathway implicated in a disease process, through intensive scientific investigation and analysis of disease mechanisms. This initial stage involves a comprehensive understanding of the pathophysiology and molecular pathways involved, often aided by advanced technologies such as genomics, proteomics, and bioinformatics. Once a target is identified, researchers embark on the arduous task of discovering and designing compounds that can modulate or interact with the target to exert a therapeutic effect.

The process of drug discovery involves various approaches, including screening large libraries of chemical compounds, rational drug design based on structural biology and computational modeling, and leveraging natural products or existing drugs as starting points for optimization. Through iterative cycles of synthesis, testing, and optimization, researchers strive to identify lead compounds with desirable pharmacological properties, such as potency, selectivity, and safety profiles. These lead compounds undergo extensive preclinical evaluation, including in vitro studies and animal models, to assess their efficacy, safety, and pharmacokinetic properties.

Successful lead compounds advance to the clinical development phase, where they undergo rigorous evaluation in human subjects through a series of clinical trials designed to assess safety, efficacy, and optimal dosing regimens. Clinical trials are conducted in multiple phases, starting with Phase I trials focused on safety and pharmacokinetics in healthy volunteers, followed by Phase II trials to evaluate efficacy and dosing in a small cohort of patients with the target disease. Phase III trials involve large-scale studies to confirm efficacy, monitor long-term safety, and establish the benefit-risk profile compared to existing treatments or placebo.

Committee Members
Speaker at Chemistry World Conference 2025 - Yong Xiao Wang

Yong Xiao Wang

Albany Medical College, United States
Speaker at Chemistry World Conference 2025 - Hossam A Gabbar

Hossam A Gabbar

Ontario Tech University, Canada
Speaker at Chemistry World Conference 2025 - Stanislaw Dzwigaj

Stanislaw Dzwigaj

Sorbonne Universite, France
Chemistry 2025 Speakers
Speaker at Chemistry World Conference 2025 - Haibo Ge

Haibo Ge

Texas Tech University, United States
Speaker at Chemistry World Conference 2025 - Thomas J Webster

Thomas J Webster

Hebei University of Technology, China
Speaker at Chemistry World Conference 2025 - Makarov Vladimir

Makarov Vladimir

Institute of Permafrost Science, Russian Federation
Speaker at Chemistry World Conference 2025 - Silvia Elizabeth Asis

Silvia Elizabeth Asis

Universidad de Buenos Aires, Argentina

Submit your abstract Today

Watsapp